Aimann Surak, Mohamed Sewidan, Mimi T. Y. Kuan, Megan Kennedy, Manoj Kumar, Joseph Y. Ting
University of Alberta. University of British Columbia.
Canada
Journal of Perinatology
J Perinatol 2026;
DOI: 10.1038/s41372-026-02837-0
Abstract
Objective: To systematically map and synthesize the available evidence on the use of vasopressin for hemodynamic support in neonates.
Study design: We conducted a scoping review to synthesize available data on indications, dosing, clinical effects, and safety.
Results: Twelve studies were included (one randomized trial, eleven observational), encompassing heterogeneous neonatal populations. Vasopressin was primarily used as rescue therapy in refractory shock, including sepsis, persistent pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. Dosing regimens varied widely. Most studies reported improvements in mean arterial blood pressure, with some demonstrating reduced vasoactive support and improved oxygenation. Effects on urine output were variable. Safety reporting was inconsistent; hyponatremia was the most commonly described adverse event, while serious ischemic complications were rarely reported.
Conclusion: Vasopressin may improve short-term hemodynamic parameters, but evidence is limited and heterogeneous, with insufficient data to guide optimal use.
Category
Class I. Persistent Pulmonary Hypertension of the Newborn
Medical Therapy. Efficacy or Lack of Efficacy
Medical Therapy. Adverse Effects or Lack of Adverse Effects
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes